AI assistant
IONIS PHARMACEUTICALS INC — Director's Dealing 2012
Jan 3, 2012
30591_dirs_2012-01-03_fcf410b6-258a-43de-aefd-beda535c8dec.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ISIS PHARMACEUTICALS INC (ISIS)
CIK: 0000874015
Period of Report: 2012-01-03
Reporting Person: CROOKE STANLEY T (Director, Chairman, President, CEO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2012-01-03 | Employee Stock Option (right to buy) | $7.25 | A | 107203 | Acquired | 2022-01-02 | Common Stock (107203) | Direct |
| 2012-01-03 | Employee Stock Option (right to buy) | $7.25 | A | 11404 | Acquired | 2022-01-02 | Common Stock (11404) | Indirect |
Footnotes
F1: Grant of 1/3/12 to reporting person of stock options under the Isis Pharmaceuticals, Inc. 1989 Stock Option Plan. 25% of the shares subject to the option will vest and become exercisable on 1/3/13. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 26,801 shares per year. The option is exercisable as to 0 shares on 1/3/12.
F2: Grant of 1/3/12 to reporting person's wife of stock options under the Isis Pharmaceuticals, Inc. 1989 Stock Option Plan. 25% of the shares subject to the option will vest and become exercisable on 1/3/13. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 2,851 shares per year. The option is exercisable as to 0 shares on 1/3/12.